Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 3/20 | 0.45 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.43 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | TNF | P01375 | 2/20 | 0.36 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.36 |
| ▸ | ABL1 | P00519 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | HCK | P08631 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.36 |
| ▸ | PRKDC | P78527 | 1/20 | 0.36 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12630708 | 0.89 | CHEK1 (0.51) | CHEK1EGLN2DGAT1PDE10ATRPA1 | |
| SCHEMBL17116597 | 0.83 | DGAT1 (0.48) | CHEK1EGLN2DGAT1PDE10ATRPA1 | |
| SCHEMBL9024185 | 0.82 | CYP11B2 (0.53) | CHEK1EGLN2DGAT1CYP11B2 | |
| SCHEMBL31588411 | 0.82 | CHEK1 (0.63) | CHEK1EGLN2DGAT1CYP11B2 | |
| SCHEMBL70602 | 0.82 | CHEK1 (0.63) | CHEK1EGLN2DGAT1CYP11B2 | |
| SCHEMBL17324161 | 0.80 | EGLN2 (0.43) | CHEK1EGLN2DGAT1PDE10ATRPA1 | |
| SCHEMBL17502178 | 0.80 | ALDH1A1 (0.50) | CHEK1EGLN2DGAT1PDE10ATRPA1 | |
| SCHEMBL17795213 | 0.80 | TNF (0.48) | CHEK1EGLN2DGAT1PDE10ATNF | |
| SCHEMBL7285319 | 0.80 | MMP3 (0.52) | CHEK1EGLN2DGAT1PDE10AJAK2 | |
| SCHEMBL2008653 | 0.80 | CHEK1 (0.45) | CHEK1EGLN2DGAT1PDE10ATRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100311729-A1 | Substituted imidazopyridazines and pyrrolopyrimidines as lipid kinase inhibitors | CAPRARO HANS-GEORG | 2010-12-09 | — | — | US | claimed |
| EP-2155202-A2 | 3,6-DISUBSTITUTED-IMIDAZO[1,2-B]PYRIDAZINES AND 3,5-DISUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINES AS PHOSPHATIDYLINOSITOL-3-KINASE INHIBITORS | Novartis Ag (CH) | 2010-02-24 | — | — | EP | claimed |
| WO-2008138889-A2 | 3, 6-DISUBSTITUTED-IMIDAZO [1, 2-B] PYRIDAZINES AND 3, 5-DISUBSTITUTED PYRAZOLO[1, 5-A] PYRIMIDINES AS PHOSPHATIDYLINOSITOL-3-KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-11-20 | — | — | WO | claimed |
| US-20170033293-A1 | ELECTRON TRANSPORT MATERIAL AND ORGANIC ELECTROLUMINESCENT DEVICE USING THE SAME | JNC CORPORATION (JP) | 2017-02-02 | — | — | US | disclosed |
| US-20100311729-A1 | Substituted imidazopyridazines and pyrrolopyrimidines as lipid kinase inhibitors | CAPRARO HANS-GEORG | 2010-12-09 | — | — | US | disclosed |
| EP-2155202-A2 | 3,6-DISUBSTITUTED-IMIDAZO[1,2-B]PYRIDAZINES AND 3,5-DISUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINES AS PHOSPHATIDYLINOSITOL-3-KINASE INHIBITORS | Novartis Ag (CH) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008138889-A2 | 3, 6-DISUBSTITUTED-IMIDAZO [1, 2-B] PYRIDAZINES AND 3, 5-DISUBSTITUTED PYRAZOLO[1, 5-A] PYRIMIDINES AS PHOSPHATIDYLINOSITOL-3-KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-11-20 | — | — | WO | disclosed |
| EP-0929508-B1 | LIQUID CRYSTALLINE (E,E)-BUTADIENE COMPOUNDS AND MIXTURES AND DEVICES CONTAINING SUCH COMPOUNDS | QINETIQ LTD (GB) | 2002-03-20 | — | — | EP | disclosed |
| US-6333082-B1 | USEFUL IN SUPER TWISTED NEMATIC LIQUID CRYSTAL DISPLAYS | QINETIQ LTD (GB) | 2001-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311729-A1 | Substituted imidazopyridazines and pyrrolopyrimidines as lipid kinase inhibitors | PI4KA, PIP5K1B, PIP4K2A | CHEK1 748/4885EGLN2 2369/4885DGAT1 782/4885 |
| US-20170033293-A1 | ELECTRON TRANSPORT MATERIAL AND ORGANIC ELECTROLUMINESCENT DEVICE USING THE SAME | SLC26A3, SLC9A1, HVCN1 | CHEK1 4506/4885EGLN2 1111/4885DGAT1 2178/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.